ESMO 2016: Ribociclib Improves Progression-Free Survival in Advanced Breast Cancer
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improved...
WHAT'S UP IN
Letrozole
MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer
IMAGE: This is Gabriel Hortobagyi, M.D. view more Copenhagen, Denmark – In a randomized,...
Study finds ribociclib improves progression-free survival for women with metastatic breast cancer
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer...
Novartis’ HR+/HER2- advanced breast cancer trial gives superior progression-free survival
You are here: Home » News » Industry news » Novartis’ HR+/HER2- advanced...
